Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
Ravi A. Madan(National Cancer Institute), James L. Gulley(National Cancer Institute), Sarah E. Lochrin(Memorial Sloan Kettering Cancer Center), William L. Dahut(National Cancer Institute), Jennifer L. Marté(National Cancer Institute), Harpreet Singh(United States Food and Drug Administration), Lisa M. Cordes(National Institutes of Health Clinical Center), Amy Hankin(National Institutes of Health), Seth M. Steinberg(National Institutes of Health), Marijo Bilušić(National Institutes of Health), Renee N. Donahue(National Institutes of Health), Jeffrey Schlom(National Cancer Institute), Fatima Karzai(National Institutes of Health), Marc R. Theoret(United States Food and Drug Administration), Philip M. Arlen(Dana-Farber Cancer Institute), William D. Figg(National Cancer Institute), Inger Rosner(Walter Reed National Military Medical Center), Anna Couvillon(National Institutes of Health), Cindy H. Chau(National Institutes of Health), Munjid Al-Harthy(National Cancer Institute), Helen Owens(National Institutes of Health), Moniquea Williams(National Cancer Institute)
Cited by 31
Related Papers
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
|Blood|2005|896
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817